Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions View by Topic View by Date Must Reads In Cardiology Cardiology for November/December 2020 Sac/val heart failure benefit extends to diabetes patients, Sedentary postmenopausal women have higher heart failure risk, Experts disagree with USPSTF’s take on pediatric blood pressure screening, GALACTIC-HF: New ‘myotropic’ drug class shows modest HFrEF benefit, Don’t miss cardiovascular risk factors in transgender patients, More must reads Cardiology for September/October 2020 Artificially sweetened drinks add to CVD risk, Cardiogenic shock rate soars in COVID-positive ACS, Benefit of rivaroxaban after limb revascularization greatest in those with comorbid CAD, Empagliflozin cut PA pressures in heart failure patients, Teen affective disorders raise risk for midlife acute MI, More must readsCardiology for July/August 2020 DAPA-CKD: SGLT2 inhibitor benefit extends to chronic kidney disease without diabetes, RATE-AF trial boosts digoxin for rate control in permanent AFib teaser, EMPEROR-Reduced: Empagliflozin's HFrEF benefit solidifies class effects, Early rhythm control in AFib gains new life, Nine antihypertensive drugs associated with reduced risk of depression, More must readsCardiology for May/June 2020 Findings of most heart failure trials reported late or not at all, Women thrive on baroreflex activation for heart failure, T2D plus heart failure packs a deadly punch, VERTIS-CV: Ertugliflozin’s CV outcomes trial confirms SGLT2i benefits, Frequent hypoglycemic episodes raise cardiac event risk, More must readsCardiology for March/April 2020 Substantial very late MACE risk after PCI for SIHD, ACEI/ARBs linked with survival in hypertensive, Chinese COVID-19 patients, HFpEF: Gender difference in sacubitril/valsartan response remains mystery, Enhanced team-based CVD care found to benefit diabetes patients, New lipid-lowering drug class slashes LDL in HoFH patients, More must readsPages1 2 3 4 5 6 7 last »
